|
nasdaq:cbay
|
5442464
|
Apr 14th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 13th, 2024 10:45PM
|
Apr 14th, 2024 10:43AM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 13th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 12th, 2024 10:36PM
|
Apr 13th, 2024 11:11AM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 12th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 11th, 2024 10:40PM
|
Apr 12th, 2024 08:06AM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 11th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 10th, 2024 11:10PM
|
Apr 11th, 2024 10:50AM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 10th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 9th, 2024 10:43PM
|
Apr 10th, 2024 04:59PM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 9th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 8th, 2024 10:54PM
|
Apr 9th, 2024 09:40AM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 8th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 7th, 2024 11:20PM
|
Apr 8th, 2024 06:38PM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 7th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 6th, 2024 10:51PM
|
Apr 6th, 2024 10:51PM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 6th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 5th, 2024 10:51PM
|
Apr 5th, 2024 10:51PM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:cbay
|
5442464
|
Apr 5th, 2024 12:00AM
|
CymaBay Therapeutics
|
12K
|
114.00
|
Open
|
|
Apr 4th, 2024 11:14PM
|
Apr 4th, 2024 11:14PM
|
We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
|
Open
|
|
Open
|
7575 Gateway Blvd
|
Newark
|
California
|
US
|
94560
|
|
Cymabay Therapeutics
|
|
Pharmaceuticals & Biotechnology
|